Correct injection method of evantumumab/carestream

Amivantamab is a dual antibody drug targeting EGFR (epidermal growth factor receptor) and MET (mesenchymal-epithelial transition factor) receptors. It is widely used to treat advanced non-small cell lung cancer (NSCLC) and other diseases. Due to its unique mechanism of action, evantumumab has become a new clinical option for the treatment of some patients who are ineffective against targeted therapies.

The dose of evantumumab is adjusted based on patient weight to ensure optimal treatment efficacy and minimal side effects. In routine treatment, 1050 mg per injection is recommended for patients weighing less than 80 kg; and 1400 mg per injection is recommended for patients weighing greater than or equal to 80 kg. The drug is given through an intravenous injection.

Injection cycle and method:

1. Used alone or in combination with lazertinib: In the initial phase, patients received two dose injections on Days 1 and 2 of Week 1, and then changed to once every two weeks starting from Week 7. This method of medication helps reduce adverse reactions and ensures a stable concentration of the drug in the body.

2. Combined use with carboplatin and pemetrexed: Initially within 4 weeks, evantumumab is injected once a week, and the dose is adjusted according to body weight. During weeks 1 to 4, patients weighing less than 80 kg receive 1,400 mg per injection, while patients weighing more than 80 kg receive 1,750 mg. Starting from the 7th week, the frequency of drug injection is adjusted to once every three weeks, and the dose is increased accordingly to 1750 mg (body weight less than 80 kg) or 2100 mg (body weight greater than 80 kg).

Evantuzumab is an intravenous drug and usually needs to be administered by professionally trained medical staff. Since the drug may cause allergic reactions or local discomfort, the injection should be performed slowly and the patient's reaction should be closely observed. During the injection process, especially in the early stages, if allergic or other discomfort symptoms occur, medical staff should be reported promptly and appropriate measures should be taken.

It is worth noting that evantumumab injections usually need to be performed in a hospital or clinical setting, and patients need to stay in the hospital for observation for at least 30 minutes to ensure that no severe allergic reactions or other side effects occur. Although the side effects of the drug are relatively few, you still need to be wary of common mild adverse reactions such as headache, nausea, and fatigue.

Reference materials:https://www.rybrevant.com/